中药牛淫合剂干预骨代谢与骨密度的研究

目的：研究牛淫合剂对绝经后骨质疏松症患者骨代谢与骨密度的影响，评价牛淫合剂抗骨质疏松治疗的疗效及可行性。方法选取2014年6月至2015年6月于深圳市第二人民医院骨科就诊的绝经后骨质疏松症患者64例，随机分为研究组32例，予口服牛淫合剂（由牛膝、淫羊藿、狗脊、丹参、仙茅、杜仲组成）；对照组32例，予口服阿仑膦酸钠片治疗；两组同时予口服钙尔奇600 mg/d与骨化三醇0.25μg/d作为基础治疗。治疗时间为6个月，并分别于服药前、服药后3个月、服药后6个月采用酶联免疫吸附试验（ELISA）测定血清中骨特异性碱性磷酸酶（serum bone alkaline phosphatase, BAP）、血清骨钙素（bone gla?protein, BGP）、抗酒石酸酸性磷酸酶5b（tartrate?resistant acid phosphatase isoform?5b, TRACP?5b），于服药前、服药后6个月采用双能X线骨密度仪（dual energy X?ray absorptiometry, DEXA）测量腰椎及髋部骨密度。结果对照组和研究组各发生2例不良反应。研究组和对照组治疗3、6个月后的BAP、BGP、TRACP?5b均较治疗前明显降低，治疗6个月后的骨密度均较治疗前显著升高，差异均有统计学意义（均P＜0.05）；研究组与对照组之间各时间点的各项指标比较，差异均无统计学意义（均P＞0.05）。结论牛淫合剂具有抗骨质疏松症的作用，其效果接近阿仑膦酸钠，并可能具有促进成骨及抑制破骨的作用。

Bone metabolism and bone mineral density intervened by NiuYin Agent

Objective To investigate the intervention of Niuyin Agent on the bone metabolism and mineral density of post?menopausal women, and evaluate the efficacy and feasibility of Niuyin Agent on the treatment of osteoporosis. Methods The subjects contained 64 post?menopausal patients with osteoporosis who have consulted in our hospital from June 2014 to June 2015. They were evenly distributed into two random groups with 32 cases in each group:the control group and the experimental group. The patients in control group were asked to take alendronate sodium tablets orally, and those in experimental group took NiuYin Agent orally for treatment. The NiuYin Agent was composed of achyranthes bidentata, epimedium brevicornum, cibotium barometz, salvia miltiorrhiza, curculigo orchioides and eucommia ulmoides. Both the groups took caltrate 600 mg/day and rocalirol 0.25μg/day orally as the basic treatment. The therapy lasted 6 months. The enzyme linked immunosorbent assay (ELISA) was done before and at the 3rd, 6th month after the treatment to observe the change of the bone turnover biomarkers, including the bone specific alkaline phosphatase (BAP), the bone gla protein (BGP) and the tartrate resistant acid phosphatase 5b (TRAP?5b). Before and 6 months after treatment, the bone mineral density of the patients’lumbar and hip was tested and statistically analyzed through the dual energy X?ray absorptiometry (DEXA). Results The serum level of BAP, BGP and TRAP?5b in the experimen?tal group and control group decreased, and the bone mineral density increased after the treatment (P<0.05 for all). There was no significant difference between the experimental group and the control group at different time points (P>0.05 for all). Conclusion NiuYin Agent is effective in anti?osteoporosis treatment, and its effect is close to that of alendronate sodium which may help promote osteogenesis and inhibit the actio of the osteoclasts.